Myovant Sciences announced the appointment of Nancy Valente, M.D. as an independent member of the company?s board of directors. In addition to her board appointment, Dr. Valente will chair the board?s nominating and corporate governance committee and be a member of the audit committee. In her most recent role, Dr. Valente was Senior Vice President and Co-lead for Global Product Development, Oncology, Hematology Development Therapeutic Area at Roche. In this role, she was responsible for setting the strategy for the department, clinical development, collaboration activities, and budget management. She played a critical role in the development of new therapies for patients with serious illnesses, including the approvals of GAZYVA?, VENCLEXTA?, POLIVY?, and HEMLIBRA?. Previously, she held various positions with increasing responsibilities at Genentech and then at Roche after Genentech was acquired by Roche, including Vice President for Global Product Development for Oncology, Hematology Franchise and Senior Group Medical Director, Leader for Hematology Development. Prior to Genentech, she served in senior-level positions at Anosys Inc. and Coulter Pharmaceutical Inc.